Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RET Inhibitors in Non-Small-Cell Lung Cancer.
Cascetta P, Sforza V, Manzo A, Carillio G, Palumbo G, Esposito G, Montanino A, Costanzo R, Sandomenico C, De Cecio R, Piccirillo MC, La Manna C, Totaro G, Muto P, Picone C, Bianco R, Normanno N, Morabito A. Cascetta P, et al. Among authors: normanno n. Cancers (Basel). 2021 Sep 1;13(17):4415. doi: 10.3390/cancers13174415. Cancers (Basel). 2021. PMID: 34503226 Free PMC article. Review.
Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells.
De Luca A, Selvam MP, Sandomenico C, Pepe S, Bianco AR, Ciardiello F, Salomon DS, Normanno N. De Luca A, et al. Among authors: normanno n. Int J Cancer. 1997 Oct 9;73(2):277-82. doi: 10.1002/(sici)1097-0215(19971009)73:2<277::aid-ijc19>3.0.co;2-c. Int J Cancer. 1997. PMID: 9335455 Free article.
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Morabito A, et al. Among authors: normanno n. Oncologist. 2009 Apr;14(4):378-90. doi: 10.1634/theoncologist.2008-0261. Epub 2009 Apr 6. Oncologist. 2009. PMID: 19349511 Free article. Review.
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F. Morabito A, et al. Among authors: normanno n. Drugs Today (Barc). 2010 Sep;46(9):683-98. doi: 10.1358/dot.2010.46.9.1516989. Drugs Today (Barc). 2010. PMID: 20967300 Review.
361 results